Strategus Launches SalesLink for Auto: First-of-Its-Kind CTV Attribution Solution Linking Ad Exposure to Real-World Outcomes
SalesLink for Auto enables advertisers to link CTV ad impressions to actual sales activity using compliant, identity-resolved data. Unlike conventional DSP reporting that offers limited, one-size-fits-all analytics, Strategus delivers custom reporting tailored to the KPIs that matter most to the advertiser—whether that's vehicle sales, dealership visits, or high-intent web engagement.
'We're proud to lead the market with an attribution solution that reflects what advertisers actually want to know—not just what the DSP can show,' said Todd Porch, CEO of Strategus. 'SalesLink for Auto provides auto marketers with proof of performance that's actionable, timely, and designed around their business goals.'
The solution is powered by Snowflake's secure data collaboration capabilities and Experian Outcomes™, a powerful measurement solution that combines identity, consumer marketing, and automotive data to quantify real-world results. This enables precise attribution at scale while protecting consumer privacy. Marketers gain near real-time insights into which campaigns are driving meaningful outcomes—like vehicle sales or dealership visits—so they can confidently optimize media strategy and prove performance.
'Our relationship with Strategus is another example of how Experian is more than just a credit bureau. We are committed to helping marketers connect digital advertising to real-world results in a privacy-first way,' said Erik Hjermstad, Vice President of Product, of Experian Automotive. 'Our identity and data assets play a critical role in enabling closed-loop attribution at scale, and we're excited to collaborate with Strategus to bring this capability to CTV advertisers.'
'It's always a challenge to determine which media channels drive traffic and how they convert. The SalesLink tool gives us a way to validate our targeting strategies by geo, audience, and media channel,' said Thomas Manning, Vice President at Star Performance Marketing. 'There are no guarantees in advertising, but the principles of advertising suggest that reaching the right audience, at the right time, with the right message leads to mindshare which translates to market share. SalesLink allows our agency to see how all of this works in one portal.'
'SalesLink bridges the gap between media exposure and real-world action, giving us a strong understanding of how our CTV campaigns prompt consumers to actually take action and make purchases,' said Scott Fanelli, Chief Revenue Officer at Edmunds. 'These insights, grounded in real consumer behavior, help Edmunds deliver even greater value to our dealer partners by making it easier to measure performance and optimize results.'
A recent Tier 2 Honda campaign shows just how effective SalesLink for Auto can be. Using attribution powered by Experian Outcomes™, the campaign drove a 133% lift in vehicle sales compared to the control group—and CTV alone delivered a 237% lift. It also led to a 3871% increase in qualified site visits and a 971% lift in dealership foot traffic. These results show how access to real vehicle purchase data at scale gives marketers the confidence to connect ad spend to business outcomes and make smarter decisions mid-campaign.
SalesLink for Auto builds on Strategus' legacy of innovation in CTV, reinforcing its role as a pioneer in Performance TV—CTV advertising that's measurable, accountable, and designed to drive results, not just reach.
Strategus plans to expand the SalesLink solution to additional verticals, including retail and financial services, giving more marketers access to closed-loop attribution in CTV campaigns—without needing to build a custom tech stack.
To learn more about SalesLink for Auto, visit strategus.com.
About Experian
Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.
We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.
We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.
About Strategus
Strategus revolutionized the advertising industry by running the first-ever programmatic CTV campaign in 2015 and continues to push the industry forward with its CTV expertise and experience. The Strategus platform delivers audience-centric campaigns to CTVs and other streaming devices by leveraging premium data partnerships, curated publisher deals and advanced targeting techniques. Strategus a full suite of managed services including attribution, targeting, optimization and analytics. Strategus has been featured on the Inc. 5000 list for five consecutive years. Learn more at strategus.com .
CONTACT INFORMATION:
SiliconAlleyMedia for Strategus
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that addresses unmet clinical needs, announced today corrections to the second paragraph of its press release under the same headline sent out on August 8, 2025. The corrected release follows: MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States. This innovative diagnostic tool aims to enhance vascular health monitoring in the region. We are also pleased to announce that we are now in-network with Blue Cross Blue Shield of Arizona, allowing us to better serve this market. Additionally, we have secured contracts that enable the reimbursement of claims through United Healthcare, Aetna, Cigna, and Humana on a nationwide basis. These claims will be reimbursed on an out-of-network basis and apply to their PPO and Medicare Advantage plans. We are happy to share that the SmartVascular Dx test is also covered by Medicare. Why SmartVascular Should Be Your Go-To Test The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions that can significantly improve health outcomes. Furthermore, we would like to remind our partners that we have collaborated with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact mjjohnson@ 866.299.8998
Business Insider
5 hours ago
- Business Insider
Snowflake Stock (SNOW) Melts as Rival Databricks Hits $100B Valuation
Cloud technology firm Snowflake (SNOW) saw its shares melt nearly 1% today as private rival Databricks reached a milestone valuation. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. It was revealed that Databricks is getting close to sealing a new funding round which will value it at $100 billion. That would be over 60% higher than its last round in December. New Funding Databricks did not reveal how much money it is raising, but back in December it hit the $10 billion mark in that funding round. The company was then valued at $62 billion. With the new cash, Databricks is looking to ramp up its AI strategy, expand its suite of AI agents and invest in its new database. It may also look at making more acquisitions in the AI space. 'We're seeing tremendous investor interest because of the momentum behind our AI products, which power the world's largest businesses and AI services,' said Databricks Chief Executive Ali Ghodsi. 'We're thrilled this round is already oversubscribed and to partner with strategic, long-term investors who share our vision for the future of AI.' Databricks recently said it generated $3.7 billion in annualized revenue in July, a growth rate of 50%. The company, which has partnerships with tech giants such as Alphabet (GOOGL) -owned Google and Amazon (AMZN) is expected to IPO at some stage in the future. It could even happen before the end of this year. Databricks had $2.6 billion in revenue in its fiscal year that ended in January, with a net retention rate over 140%. In the first quarter of the new fiscal year, nearly 50 of Databricks' 15,000-plus customers are spending over $10 million annually. Snow Joke Both Databricks and Snowflake sell data analytics and data-management software that runs on cloud-computing platforms. Snowflake has a market cap of $66 billion, so the challenge from a stronger Databricks is obvious. But the opportunity for both firms in an expanding AI field is just as clear. Snowflake's share price has climbed over 28% in the year-to-date and over 50% in the last 12 months – see below. The company also reported a strong start to the year with Q1 product revenue reaching $997 million, a 26% year-over-year increase. Snowflake also added 451 net new customers in Q1, growing 19% year-over-year. What are the Best AI Stocks to Buy Now?
Yahoo
5 hours ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
